Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-CTLA-4 monoclonal antibody

Tremelimumab (Specialist drug)

Brand names: Imjudo

Tremelimumab is a monoclonal antibody immune checkpoint inhibitor used under specialist supervision, typically combined with other agents, for cancers including hepatocellular carcinoma and non-small-cell lung cancer.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks CTLA-4 on T cells, removing an inhibitory checkpoint and enhancing T-cell-mediated antitumour immune responses.

Prescribing in practice

  • Immune-mediated adverse reactions can affect any organ (including colitis, hepatitis, pneumonitis and endocrinopathies) and may require corticosteroids and treatment interruption.
  • It is a specialist immunotherapy usually given in combination regimens, for example with durvalumab.
  • Pre-existing autoimmune disease warrants careful assessment before use per the SPC.

Monitoring

Monitor liver and thyroid function, blood glucose and for any new immune-related symptoms before and during treatment.

Counselling the patient

  • Report new diarrhoea, breathlessness, severe tiredness or any unexplained symptoms promptly, even after treatment ends.
  • Carry an alert card and tell other clinicians you are receiving immunotherapy.
  • Effective contraception is advised during and after treatment.

Evidence & guidelines

Use in combination immunotherapy is supported by trials such as HIMALAYA and POSEIDON and relevant NICE appraisals.

Reference: NICE TA887; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways